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Abstract
In pharmacoepidemiology, comparison studies can provide a useful estimate of the level of increased or decreased risk of 
specific events with a medication (through a measure of effect). A key focus of pharmacoepidemiological studies is the safety 
and effectiveness of medicines in their real-world use, and adequate comparisons of effect estimates are critical. However, 
consideration of guidelines, pharmacoeconomic assessments, and policies for reimbursement have made comparisons in 
pharmacoepidemiological studies far more difficult to conduct in recent years. Where certain subject characteristics influence 
the probability of being exposed to a treatment, this can introduce issues of selection bias and confounding. Methodologies 
are available to minimise selection bias (through case-only and randomised study designs) and deal with confounding (such as 
regression modelling or propensity score matching methods), however these each have their own limitations. Where prescrib-
ing guidelines are present, conducting comparisons in pharmacoepidemiology produces many challenges and not all of these 
can be easily overcome. Patient channelling can be more frequent with adherence to clinical guidelines compared with when 
prescribing decisions by doctors are based predominantly on their clinical judgement. Use of a contextual cohort could be 
considered as an option to characterise the adoption of new medications into clinical practice and describe the prevalence of 
clinical characteristics and risk factors in the two cohorts, rather than compare event rates and produce an estimate of effect.
Key Points 
Guidelines, pharmacoeconomic assessments, and poli-
cies for reimbursement can make comparisons in phar-
macoepidemiological studies difficult to conduct due to 
selection bias and confounding.
Use of a contextual cohort could be considered as an 
option to characterise the adoption of new medications 
into clinical practice and describe the prevalence of clini-
cal characteristics and risk factors.
1 Introduction
Pharmacoepidemiological studies examine the use of medi-
cations and any effects from their use (including adverse 
drug reactions) in populations of interest [1]. While safety 
information from randomised controlled clinical trials 
(RCTs) is useful in providing a measure of effect for adverse 
events (comparing the new treatment with another treatment) 
[2], the primary endpoint of these trials may not be to com-
pare safety but rather to show efficacy. Trials can be small 
in size and insufficiently powered to inform on rare adverse 
events. In addition, they often have exclusion criteria that 
will not always apply in real-life use, making them unrepre-
sentative of the medication’s use in the general population 
[3]. RCTs are most commonly conducted in the premarket-
ing phase of a medicinal product, while other study designs 
are used in the postmarketing phase to enable real-life use to 
be monitored. Pharmacoepidemiological comparison stud-
ies are used to determine if a new treatment has a reduced, 
equal, or greater risk of adverse events than other available 
treatments in real-world populations, even in cases where the 
comparisons are problematic or inappropriate.
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However, consideration of guidelines, pharmacoeconomic 
assessments, and policies for reimbursement have made phar-
macoepidemiological studies far more difficult to conduct in 
recent years. Adherence to guidelines for prescribing issued 
by organisations that conduct health technology assess-
ments, such as the National Institute for Health and Clinical 
Excellence (NICE) in the UK [4] and, internationally, local 
formulary restrictions (where prescription of medications is 
restricted to those approved by a committee), can significantly 
impact prescribing decisions that control allocation to treat-
ment, with little variation based on physician judgement and 
choice. In the absence of prescribing guidelines, differences 
between patients prescribed a medication and those who are 
not may mean it is inappropriate to compare the two cohorts. 
For instance, health insurance policies can restrict treatment 
options that prescribers can provide to an individual patient. 
Patients may not be prescribed new medications unless it 
has been established that they are intolerant to or have not 
responded to another existing medication, or they have specific 
characteristics or conditions which are a contraindication for 
use of another treatment. These patients may have more severe 
forms of the indicated illness compared with patients who 
sufficiently respond to standard treatment. Alternatively, new 
treatments may be provided to the healthiest patients who are 
considered at lowest risk of adverse events. Cost of the medi-
cation is often a major consideration as it may not be recom-
mended for prescription unless there is evidence that a patient 
cannot use a cheaper medication or that the more expensive 
medication has superior efficacy. While reducing costs and 
adhering to budgets is important, it can have a major impact 
on pharmacoepidemiological research. Where certain subject 
characteristics influence the probability of being exposed to a 
treatment, this can introduce systematic bias caused by selec-
tion bias and confounding.
In such situations, the characteristics between patients 
who are prescribed the medication under study may be 
substantially different to patients prescribed an alternative 
treatment (or no treatment), and comparisons made through 
conventional pharmacoepidemiological designs may there-
fore be inappropriate. The contextual cohort methodology 
can be used in these instances to overcome limitations and 
challenges encountered if conventional study designs were 
applied. These limitations may be encountered in studies 
conducted across different populations, therefore there is 
wide applicability of the contextual cohort approach.
2  Existing Pharmacoepidemiological Study 
Designs
In pharmacoepidemiology, observational designs are most 
commonly applied. These include classic designs such as the 
cohort and case-control designs, and case-only designs such 
as the case-crossover and self-controlled case series. These 
designs allow comparison of treatment effects between dif-
ferent groups of patients, which is a key aspect of pharma-
coepidemiology; however, these designs are susceptible to 
bias and confounding. Minimisation of selection bias can be 
challenging where guidelines dictate treatment choices. Con-
founding also needs to be considered and if all confound-
ing factors are not properly adjusted for in the analysis, this 
could result in an incorrect estimate of the measure of effect 
[5]. In case-only designs, the patient is used as their own 
control. This eliminates confounding from non-time-variant 
factors (i.e. factors that do not change over time), although 
time-varying confounding, such as changes in concomi-
tant medication, still needs to be considered [6, 7]. Case-
only designs are based on a number of assumptions, which 
restrict the use of these studies in pharmacoepidemiology 
to only certain events and exposures; use in inappropriate 
settings could result in bias [6, 7]. Restriction is a method 
of controlling confounding at the design stage. The method 
involves restricting the study population on one or more 
baseline covariates, to eliminate the confounding effect of 
that covariate [8]. Study participants are limited to one cat-
egory of the confounding factor. For example, if restricting 
on smoking status, one might include only non-smokers in 
the study to eliminate the confounding effect of smoking. 
However, the method suffers some limitations, such as the 
inability of examining the effect of the restricted variable 
and limiting the sample size and power. Where the interest 
is in examining outcomes in the real-world, restriction may 
not be a suitable approach.
Pragmatic trials, such as the series of Randomised Evalu-
ations of Accepted Choices in Treatments (REACT) trials 
[9, 10], can be used to bridge the evidence gap between 
RCTs and pharmacoepidemiological studies. Their ran-
domised nature removes the issues of selection bias and con-
founding, but inherent limitations remain. Physicians could 
be unwilling to prescribe branded medication to patients 
against formulary guidelines, potentially affecting the use 
of a randomised study design. There may also be difficulty in 
recruiting patients into the study, therefore obtaining sample 
sizes with sufficient power may not be possible. Other issues 
relate to the choice of drug and initial indication of a new 
drug, in addition to outcome definitions and the requirement 
for safety reporting.
The choice of a study comparator is another issue related 
to pharmacoepidemiological studies. Most commonly, the 
choice of a study comparator when examining a new treat-
ment would be a current, well-established medication that 
is usually the most widely used treatment for the disease 
in question. However, the use of such a comparator can be 
a challenge in observational research if a new treatment 
is unlikely to be administered to the same population of 
patients receiving the current treatment. The two treatment 
Comparisons in Pharmacoepidemiology and the Role of the Contextual Cohort
groups could be different in many aspects, such as age of 
the patient, disease severity, concomitant medications, 
comorbidities, and other risk factors. In this case, a cohort 
based on the counterfactual ideal, which is equivalent to the 
cohort of interest except for the exposure, may be difficult to 
create. Another option for choosing a comparator is to use 
another new treatment for the same indication, where one 
is available. While patient characteristics are more likely to 
be similar in real-life use, the main problem with this option 
is that safety in relation to the usual standard of care cannot 
be examined. It may be that the choice of comparator has 
to remain reliant on the choice of study design and whether 
selection bias can be minimised effectively. An important 
point to consider in the study design is that differences in 
patients’ characteristics between those who receive the new 
treatment and patients who receive the comparator are aug-
mented (thus introducing systematic differences) when the 
prescribing of the new treatment is mostly, or nearly always, 
in compliance with guidelines that are adhered to, compared 
with doctors prescribing only on the basis of their knowl-
edge and clinical judgement.
2.1  Managing Limitations 
in Pharmacoepidemiological Studies
Where confounding is likely to be an issue in pharmacoepi-
demiological comparison studies, a decision needs to be 
made on how to deal with this at either the design stage or 
the analysis stage of a study. At the design stage, randomi-
sation is the favoured technique to control for confounding 
where appropriate, since potential confounders are randomly 
distributed between groups [11]. It also deals with selection 
bias, unlike other methods that deal with confounding. How-
ever, in pharmacoepidemiology, randomisation is not often 
practical when use of a medication in real-life populations 
needs to be explored. Therefore, statistical methods are often 
employed to handle observed confounders at the analysis 
stage; such methods include, but are not limited to, stratifi-
cation, regression analysis, and propensity scores. However, 
such methods possess limitations of their own. For example, 
regression requires information on all potential confound-
ing factors to have been collected and cannot account for 
unmeasured confounders. Models can become unstable 
when attempting to account for too many confounding fac-
tors, particularly when the sample size is small. In general, 
10 observations per risk factor are needed in a model to 
ensure stability [11]. As such, small studies with multiple 
potential confounders may not be analysable using regres-
sion techniques. Conversely, the use of propensity scores 
involves ‘throwing out’ patients who cannot be matched, 
and this can cause considerable problems where patients 
have completely different risk profiles and therefore unequal 
probability of receiving treatment. If a large number are 
excluded, then the representativeness of patients in the anal-
ysis may be questioned and may no longer reflect patients 
in routine clinical practice. It may be that construction of 
propensity scores identifies that the two treatment groups 
are not comparable at all, or that the analysable cohort is a 
very small proportion of the recruited cohort [12]. In com-
parison to regression models, a larger number of potential 
confounders can usually be accounted for with propensity 
scores, and a small study with a low number of events is still 
analysable [13]. However, evidence is limited that propen-
sity score methods provide substantially different estimates 
compared with multivariable regression analyses to control 
confounding [14]. Use of a contextual cohort provides an 
alternative method, avoiding some of the limitations seen 
with these more commonly used methods to deal with bias 
and confounding in pharmacoepidemiology.
3  The Contextual Cohort
Comparisons based on the counterfactual ideal in pharma-
coepidemiology are sometimes not feasible when examin-
ing real-life medicinal use. A different approach is to gather 
information on a contextual cohort in addition to the group 
receiving the treatment of interest, to determine the prescrib-
ing patterns of two products licensed for a similar indication 
at baseline. Comparison of the reasons for prescribing in the 
treatment group against a comparator group using stand-
ard (existing) therapy can put utilisation observations into 
context. The distinguishing feature between the contextual 
cohort approach and a conventional comparator group is that 
no comparison of measure of effect is made between the two 
cohorts (e.g. no risk ratio is calculated).
3.1  Use of Contextual Cohort Methods
Contextual cohort methods may be useful when comparative 
pharmacoepidemiological study designs are inappropriate, 
especially when there are systematic differences in certain 
characteristics or risk factors between the two groups to be 
compared. The use of a contextual cohort in such situations 
avoids the limitations that would be encountered when using 
a conventional design, such as biases, confounding, and 
obtaining a sample size appropriately powered to make com-
parison, because no formal comparisons are made between 
the two cohorts.
The method allows comparison of patient characteristics, 
distribution of risk factors for the outcome of interest, and 
non-clinical reasons for prescribing in each group. This is 
particularly useful for newly marketed medications, where 
the adoption of the product into clinical practice can be char-
acterised. For instance, it might be possible to determine the 
reasons to choose prescribing the newer product over a more 
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established medication. Where patients are switched from 
established medications to new medications, the reasons for 
switching can also be explored and the risk profile of switch-
ers can be examined further.
3.2  Methodology
The goal of contextual cohort methodology is not to make 
formal comparisons of risk of a primary outcome between 
the drug of interest and the product used in the contextual 
cohort. It is the differences between the groups in terms of 
patient characteristics that are of interest, rather than differ-
ences in outcome.
Therefore, patient characteristics for both the primary 
group of interest and the contextual cohort are examined 
separately. These may be tabulated and descriptive statis-
tics used to describe the characteristics of each cohort. It is 
acceptable to calculate absolute risks, rates, or odds of an 
outcome in each group, but to calculate their ratio would be 
inappropriate.
This approach will highlight biases and/or confound-
ers that might have affected results had the study been 
conducted using a conventional pharmacoepidemiological 
design, where formal comparison of the effect measures in 
each group would have been calculated (through risk ratio, 
rate ratio, odds ratio).
3.3  Analyses and Interpretation
The aim of using a contextual cohort design is to character-
ise the adoption of a new medication into clinical practice 
and explore the factors that drive prescribing of the new 
medication instead of existing options. Comparison of the 
patient cohorts prescribed each medication identifies pos-
sible differences in factors, such as setting, prevalence of 
(non-clinical) reasons for prescribing, physician prescribing 
preference factors, and those clinical characteristics that are 
known risk factors for the primary outcomes of interest. The 
key purpose of the use of a contextual cohort is to explore 
the variation in the distribution and determinants of prog-
nostic and clinical risk factors at baseline.
Use of the contextual cohort negates the need to control 
for confounding, since the purpose is not to compare esti-
mates of effect. However, other modelling techniques can be 
considered to explain variation in prescribing. For example, 
multi-level modelling can provide insight into sources of 
variability. An alternative approach to examine prescrib-
ing variability between two cohorts is the use of propensity 
scores for descriptive purposes only. Propensity scores can 
be calculated for each cohort to examine the distribution 
for each treatment, rather than for matching purposes, as 
is done in conventional pharmacoepidemiological studies. 
This allows exploration of the differences between the two 
cohorts, focusing on whether patients have any overlap in 
the predicted probability of receiving treatment between the 
treatment of interest and the contextual cohort. If little to no 
overlap is detected, then this would support the assertion 
that use of a comparator based on the counterfactual ideal 
is inappropriate.
3.4  Limitations of Contextual Cohort Methodology
The choice of contextual cohort can be difficult, particularly 
if more than one existing treatment is used for the same 
indication. In the majority of cases, it might be considered 
most appropriate to use the treatment that has been most 
commonly used or has been marketed for the longest dura-
tion as the standard of care. Alternatively, it might be that 
the medication of interest is expected to target a similar 
user population to that of another treatment already used 
in clinical practice, and therefore analysis of the reasons 
for prescribing one versus the other would be of interest. 
The choice of contextual cohort will therefore depend on 
the medication of interest and the question(s) that the study 
seeks to answer.
While the contextual cohort method is useful to highlight 
different patient characteristics between the two groups and 
to generate baseline knowledge, it is not possible to deter-
mine whether one medication has excess risk of an outcome 
versus the other because the patient characteristics are often 
too dissimilar to make direct comparisons. Analyses taking 
into account both patient groups are therefore limited. Where 
calculating risk within each cohort though, comparisons can 
be made with corresponding clinical trial data or observa-
tional data. This allows the risks to be related to the known 
literature, without attempting a formal comparison between 
study drugs. The collection of a broad range of data on risk 
factors also allows quantification of risk factors for the out-
come of interest. With regard to sample size calculations, 
studies that use a contextual cohort can be powered based on 
known risk from clinical trials. The principle is to estimate 
the risk so that it lies within an acceptable range (margin 
of error) of the estimate from clinical trials, assuming this 
represents the true value. Ideally this margin of error (also 
called precision) should be as narrow as possible so that the 
frequency is estimated as precisely as possible. The sample 
size is chosen so that it will yield a confidence interval of a 
predefined width for the risk.
4  Examples of Contextual Cohort Use
The contextual cohort design has been utilised previously in 
a Specialist Cohort Event Monitoring (SCEM) study [15], 
evaluating the safety and utilisation in patients prescribed 
rivaroxaban for the prevention of stroke in patients with 
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atrial fibrillation (AF), the treatment of deep vein thrombosis 
(DVT) and pulmonary embolism (PE), and the prevention of 
recurrent DVT and PE in a secondary care setting in England 
and Wales, using the SCEM technique [16–18]. Rivaroxaban 
is a direct oral anticoagulant (DOAC), a class of drug recom-
mended as an alternative to conventional anticoagulant treat-
ment with vitamin K antagonists (VKAs) in international 
guidelines [19, 20]. The Rivaroxaban Observational Safety 
Evaluation (ROSE) study included a contextual cohort of 
patients prescribed warfarin, in order to compare reasons 
for choice of anticoagulation type and to explore differences 
in both the clinical setting of initiation and baseline risk of 
bleeding and stroke [16–18]. Bleed outcomes could be esti-
mated, but due to the differences between the rivaroxaban 
and warfarin cohorts, direct comparisons between them were 
not appropriate. An evidence-based national technology 
appraisal (TA) for the use of rivaroxaban in the prevention 
of stroke and embolism in people with AF was first issued by 
NICE in May 2012, while a TA for the use of rivaroxaban in 
treating PE and preventing recurrent venous thromboembo-
lism was published by NICE in June 2013 [21]. In the UK, 
the National Health Service (NHS) is legally bound to fund 
and resource medicines and treatments recommended by 
NICE TAs. In addition, local NHS trusts maintain formular-
ies that also govern prescribing practices. These guidelines 
influence prescribing of rivaroxaban and warfarin in the UK, 
which is why differences between the two cohorts arise. 
Within the ROSE study, it was found that prescribing vari-
ability was dominated by differences between NHS trusts 
and between prescribers (within trusts) [22]. Some patient 
factors were important in treatment choice but accounting 
for patient differences did not fully explain the variance both 
between prescribers (within trusts) and between trusts [22].
Meanwhile, contextual factors have been examined in 
previously published literature, especially within social sci-
ences. These studies refer to the concept of the contextual 
phenomenon, where health status varies based on different 
environmental influences [23, 24]. One such example is that 
of a review of RCTs investigating the performance of health-
care workers in sub-Saharan Africa [25]. The purpose of 
including contextual factors in the review was to understand 
how differences in these contextual factors contribute to dif-
ferences in the local effect of interventions to improve per-
formance [25]. In this study, contextual factors were grouped 
into the categories ‘management’, ‘staffing’, and ‘local envi-
ronment’ [25]. The authors concluded that the importance of 
local contextual influence in interventional trials should be 
reflected in the planning, design, and reporting of the study 
results [25]. A second example used contextual information, 
such as factors that can affect the impact of an intervention, 
to understand whether programmes are providing interven-
tions to those in need and reasons for or against this [26]. 
In both of these studies, contextual data were found to be 
important in improving interventions in real-world settings 
[25, 26].
A review of qualitative research addressing antibiotic 
prescribing in long-term care facilities highlighted that pre-
scribing is heavily influenced by the context of care [27]. 
Contextual factors affecting antibiotic prescribing in this 
setting included a lack of resources (including doctors and 
diagnostic equipment), the relationship between the health-
care provider and patient, and whether care in the long-term 
facility was a priority over hospitalisation [27]. A similar 
review describing antibiotic prescribing in hospitals also 
assessed contextual aspects of prescribing; it was determined 
that such factors are partly responsible for the differences in 
antibiotic use [28].
5  Conclusion
Overall, the contextual cohort is an appropriate option within 
pharmacoepidemiological study designs to consider when a 
conventional comparator may not be available or appropri-
ate, or where the primary study purpose is to explore the 
differences between treatment groups rather than compare 
effect estimates. Where prescribing guidelines are present, 
conducting comparisons in pharmacoepidemiology produces 
many challenges that are not often correctly overcome by 
using conventional pharmacoepidemiological study designs. 
Use of a contextual cohort could be considered as an option 
to characterise the adoption of new medications into clinical 
practice and describe the prevalence of clinical characteris-
tics and risk factors in the two cohorts, rather than compare 
event rates and produce an estimate of effect.
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